Current Management Strategies for Stenotrophomonas maltophilia
Abstract
Optimal therapeutic strategies for Stenotrophomonas maltophilia infections remain largely undefined. Current evidence tentatively supports combination therapy in immunocompromised hosts and severe infections, as no single agent reliably provides bactericidal activity. However, no specific regimen has been proven superior. Traditional agents such as trimethoprim-sulfamethoxazole, minocycline, and levofloxacin remain essential components of treatment. New antimicrobials, including cefiderocol and aztreonam-avibactam, are promising options, but further clinical data are required to validate their efficacy. To date, no randomized controlled trials have been conducted in S maltophilia infections, and well-designed studies are urgently needed to provide definitive answers.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.